On May 13, 2026, the U.S. Food and Drug Administration (FDA) approved the all-oral combination of decitabine and cedazuridine (Inqovi®, Taiho Oncology) plus venetoclax (Venclexta®, AbbVie/Genentech) for adults with newly diagnosed acute myeloid leukemia (AML) who are ≥75 years of age, or who have comorbidities precluding intensive induction chemotherapy. This approval establishes a fully oral, non-intensive AML regimen — replacing the subcutaneous or intravenous hypomethylating agent (HMA) component of the current standard, azacitidine + venetoclax, with an oral HMA. It substantially expands treatment access for older and frail AML patients. This article summarizes the pivotal data, safety, and the regulatory and clinical implications.
Target Patient Population
- Adults (≥18 years) with newly diagnosed AML (de novo and secondary)
- ≥75 years of age, or
- Comorbidities that preclude intensive induction chemotherapy (e.g., the 7+3 standard)
- Performance status compatible with oral therapy
- Not labeled for patients fit for intensive induction
Pivotal Trial Overview
The approval is supported by data from ASCERTAIN-AML (NCT04657081) and integrated confirmatory studies evaluating the all-oral combination of Inqovi (a fixed-dose oral combination of decitabine 35 mg and cedazuridine 100 mg) with oral venetoclax in newly diagnosed AML patients unfit for intensive chemotherapy.
| Item | Detail |
|---|---|
| Trial IDs | NCT04657081 (ASCERTAIN-AML) and related |
| Design | Open-label, single-arm primarily, with comparative cross-study reference to Phase 3 VIALE-A |
| Approval-supporting N | ~150 newly diagnosed AML patients unfit for IC |
| Population | Newly diagnosed AML, ≥75 years or unfit for IC |
| Intervention | Inqovi 35/100 mg orally once daily × 5 days (28-day cycle) + Venetoclax 400 mg orally once daily (post ramp-up) |
| Reference comparator | Azacitidine 75 mg/m² SC/IV × 7 days + venetoclax (VIALE-A historical control) |
| Primary endpoint | Complete response (CR) rate; CR + CRi rate |
| Key secondary endpoints | Overall survival (OS), MRD negativity, transfusion independence, safety |
Inqovi’s mechanistic innovation is the pairing of decitabine (a DNA methyltransferase inhibitor) with cedazuridine (a cytidine deaminase inhibitor). Oral decitabine is otherwise rapidly inactivated in the gastrointestinal tract by cytidine deaminase; the addition of cedazuridine produces oral exposures equivalent to subcutaneous azacitidine or intravenous decitabine. Inqovi was previously approved in 2020 for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML); this approval extends its indication to AML.
Venetoclax in combination with azacitidine has been the standard for newly diagnosed AML unfit for intensive chemotherapy since the VIALE-A trial (NEJM 2020). This approval is built around the hypothesis that replacing the parenteral HMA component with oral Inqovi delivers comparable clinical outcomes.
Key Efficacy Results
| Endpoint | Inqovi + Ven (all-oral) | Historical control (Aza + Ven, VIALE-A) |
|---|---|---|
| CR rate | ~35–40% | ~36% |
| CR + CRi rate | ~65% | ~66% |
| Transfusion independence (RBC + platelet) | ~45% | ~49% |
| MRD negativity (among CR/CRi) | ~40% | Comparable |
| Median OS | Follow-up ongoing | 14.7 months (VIALE-A) |
Efficacy outcomes fell within a statistically comparable range to the VIALE-A historical control of azacitidine + venetoclax. This approval establishes the clinical and regulatory feasibility of a fully oral non-intensive AML regimen.
Long-term OS and the durability of MRD negativity remain subjects of post-marketing follow-up.
Safety Profile
Adverse events were dominated by AML-treatment-typical myelosuppression and infection risk. Oral administration produced manageable gastrointestinal toxicity.
| Adverse Event | All grades | Grade ≥3 |
|---|---|---|
| Neutropenia (including febrile) | ~80% | ~70% |
| Thrombocytopenia | ~65% | ~50% |
| Anemia | ~60% | ~30% |
| Infections (sepsis, pneumonia) | ~60% | ~35% |
| Nausea / vomiting | ~35% | <5% |
| Diarrhea | ~25% | <3% |
| TLS (venetoclax ramp-up) | <5% | <2% |
Prescribing information retains existing Inqovi warnings (serious myelosuppression, embryo-fetal toxicity) and emphasizes TLS risk during venetoclax ramp-up. The standard AML-indication venetoclax ramp-up of 100 → 200 → 400 mg over three days applies, with inpatient monitoring recommended for high-risk patients. Because both components are oral, medication adherence and timely symptom reporting become more pivotal to outcomes — making care-team and family coordination central to the regimen’s real-world success.
Regulatory and Clinical Significance
The implications can be organized around three axes.
(1) Establishing a fully oral non-intensive AML regimen. AML has historically required inpatient-centered intensive chemotherapy (“induction → consolidation → optional transplant”). VIALE-A introduced “azacitidine + venetoclax” as an outpatient-capable standard for unfit patients. This approval takes the next step — making the regimen injection-free and entirely oral. This is particularly meaningful for home-based and community oncology delivery of AML care.
(2) Broadened access for older AML patients. Patients ≥75 years of age, or with comorbidities precluding IC, account for 50–60% of newly diagnosed AML. An oral regimen substantially reduces the visit burden by eliminating monthly seven-day cycles of subcutaneous azacitidine clinic visits and the associated transportation and caregiver costs. Community hematology centers — geographically more accessible — can now manage the full regimen.
(3) A Taiho Oncology / AbbVie cross-company combination as a regulatory model. This approval combines an oral HMA developed by Taiho Oncology (the U.S. subsidiary of Otsuka Holdings’ Taiho Pharmaceutical) with AbbVie / Genentech’s BCL-2 inhibitor. Inter-company combination regimens advancing through approval are a constructive precedent for expanding patient benefit while serving both companies’ commercial trajectories. Approval status in other jurisdictions is determined separately and should be confirmed via local regulatory authorities.
My Thoughts and Future Outlook
The treatment of older AML patients has changed substantially in the last several years. VIALE-A made outpatient therapy with subcutaneous azacitidine + oral venetoclax feasible; this Inqovi + venetoclax approval now eliminates the injection altogether. For patients, the absence of monthly seven-day subcutaneous clinic visits is meaningful. For families, caregiver burden falls. For clinical operations, outpatient scheduling tightens. These are real-world wins on the implementation side.
That said, the efficacy is best described as “within the comparable range” of VIALE-A, not “superior”. Mature OS data, MRD durability, and outcomes within key cytogenetic / molecular subgroups (IDH1/2, FLT3, TP53 mutations) await post-marketing analysis. The accurate reading is “equally effective in oral form”, not “better because oral.”
The natural next directions are (1) combinations of oral HMA + venetoclax with targeted agents such as IDH1/2 or FLT3 inhibitors, (2) oral maintenance regimens for patients achieving MRD negativity, and (3) oral HMA-based post-transplant maintenance. AML therapy is approaching a state in which a meaningful fraction of care can be delivered entirely in oral form. This approval is one of the more important milestones along that arc.
This article was compiled and summarized by Morningglorysciences based on FDA public materials, Taiho Oncology / AbbVie press releases, peer-reviewed publications of ASCERTAIN-AML and related trials, and other sources. Treatment decisions should always be made in reference to the original publications, the most recent prescribing information, and local clinical practice guidelines.
Comments